Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease

Официальное название

Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Factorial Randomized Clinical Trial

Обзор

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 1 diabetes (T1D) and is associated with increased cardiovascular and metabolic risk. However, evidence regarding effective therapeutic strategies for MASLD in T1D remains scarce. Lifestyle modification has shown benefits in obesity and type 2 diabetes, whereas butyrate, a microbiota-derived short-chain fatty acid, has emerged as a potential therapeutic approach because of its anti-inflammatory and metabolic effects. This study aims to evaluate the efficacy of intensive lifestyle modification, butyrate supplementation, or their combination on hepatic steatosis in individuals with T1D and MASLD. Methods: BEAM-T1D is a factorial, randomized, 6-month, parallel-group, placebo-controlled clinical trial conducted at the Regional University Hospital of Malaga. A total of 200 adults with T1D and MASLD will be randomized (1:1:1:1) to receive: (1) standard lifestyle recommendations plus placebo; (2) intensive lifestyle modification plus placebo; (3) standard lifestyle recommendations plus butyrate; or (4) intensive lifestyle modification plus butyrate. Intensive lifestyle modification includes a hypocaloric Mediterranean diet and promotion of physical activity. Participants randomized to butyrate will receive 2.25 g/day of microencapsulated sodium butyrate. The primary endpoint will be the change in controlled attenuation parameter (CAP) measured by transient elastography (FibroScan®). Secondary outcomes include changes in liver fat content, insulin resistance, metabolic control, body composition, inflammatory markers, gut microbiota composition, and short-chain fatty acid concentrations. Results: Participant recruitment is expected to begin in October 2025. The study will evaluate the independent and combined effects of butyrate supplementation and intensive lifestyle modification on hepatic steatosis and metabolic outcomes in individuals with T1D and MASLD. Conclusion: The BEAM-T1D study will provide novel evidence regarding the potential role of butyrate and intensive lifestyle modification in the management of MASLD in T1D. If effective, these interventions could represent feasible and scalable therapeutic strategies for a population with limited evidence-based treatment options.

Вмешательства

• Другое Intensive lifestyle modification (hypocaloric Mediterranean diet and promotion of physical activity)
  Participants will be advised to follow a Mediterranean diet, characterized by the use of olive oil as the main source of fat, regular consumption of vegetables, fruits, legumes, and fish, reduced consumption of red meat and processed meats, and elimination of sugar-sweetened beverages, industrial pastries, and confectionery. The Mediterranean diet will include a 30% energy restriction based on estimated energy needs (Harris-Benedict equation). Participants will also be advised to perform ≥150 mi
• Пищевая добавка Butyrate
  Participants randomized to this group will receive microencapsulated sodium butyrate (MSB). Each sachet contains 750 mg sodium butyrate and 1750 mg triglyceride matrix (total 2,500 mg). Participants will take 3 sachets daily (total daily dose: 2.25 g butyrate): one in the morning, one at midday, and one in the evening.
• Пищевая добавка Intensive lifestyle modification + butyrate
  Participants will undergo both intensive lifestyle modification and receive butyrate as described above. This study will be placebo-controlled: participants not randomized to butyrate will receive placebo sachets identical in size, color, appearance, and taste to the investigational product but without butyrate. Placebo will also be taken three times daily following the same schedule.

Первичные конечные точки

• Changes in Controlled Attenuation Parameter (CAP) by hepatic elastography (FibroScan®): Controlled Attenuation Parameter (CAP) [Срок оценки: Baseline, 3 month and 6 month]
• Changes in Controlled Attenuation Parameter (CAP) by hepatic elastography (FibroScan®): Liver Stiffness Measurement [Срок оценки: Baseline, 3 month and 6 month]

Вторичные конечные точки (12)

• Changes in insulin resistance: eGDR [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: Glucose [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: HbA1c [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: Average sensor glucose [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: Glucose Management Indicator (GMI) [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: Time in range (TIR) [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: Time Above Range (TAR) [Срок оценки: Baseline, 3 months and 6 months]
• Changes in metabolic control: Time Below Range (TBR) [Срок оценки: Baseline, 3 months and 6 months]
• Changes in body composition: Weight [Срок оценки: Baseline, 3 months and 6 months]
• Changes in body composition: Body mass index (BMI) [Срок оценки: Baseline, 3 months and 6 months]
• Changes in body composition: Muscular area of rectus anterior [Срок оценки: Baseline, 3 months and 6 months]
• Changes in body composition: Fat mass [Срок оценки: Baseline, 3 months and 6 months]

Критерии участия

Критерии включения

• Age 18-75 years.
• Type 1 diabetes.
• MASLD: Defined by a Controlled Attenuation Parameter (CAP) measured by Fibroscan® ≥248 dB/m (40).
• Signed informed consent.

Критерии исключения

• History of alcohol consumption > 50 g/day in men or > 30 g/day in women for 3 consecutive months in the last year.
• Patients with impaired liver function (total bilirubin > 2.0 mg/dL).
• Hemochromatosis, Wilson's disease, or autoimmune hepatitis.
• History of cancer (except basal cell carcinoma) in the past 5 years or active cancer of any type.
• Known infection with HIV, HBV, HCV, or any other infection that may cause liver disease.
• Severe underlying diseases that, in the investigators' judgment, constitute an exclusion criterion for study participation.
• Reduced life expectancy.
• Pregnant or breastfeeding women.
• Documented history of intolerance/allergy to butyrate.
• Participation in another clinical trial within 30 days prior to study entry.
• Inability to comply with scheduled visits.
• Use of antibiotics, prebiotics, or probiotics (in pharmacological form or as supplements, not as part of usual diet) in the month prior to inclusion in the study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Факторный дизайн

Маскирование

Двойное слепое

Основная цель

Лечение

Центры проведения

Испания · 1 центр

• Hospital Regional Universitario de Málaga, FIMABIS — Málaga

Идентификаторы

NCT: NCT07684248 · BEAM-T1D Study

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗